Works by Chia-Chi Lin


Results: 96
    1
    2
    3
    4
    5
    6
    7

    Barriers to publishing early phase clinical trials: the oncologists' perspective.

    Published in:
    Oncologist, 2025, v. 30, n. 4, p. 1, doi. 10.1093/oncolo/oyaf042
    By:
    • Lucassen, Merel J J;
    • Bergmann, Pedro;
    • Husson, Olga;
    • Banerji, Udai;
    • Basu, Bristi;
    • Melero, Ignacio;
    • Calvo, Emiliano;
    • Cassier, Philippe A;
    • Drilon, Alexander;
    • Fong, Peter C;
    • Garralda, Elena;
    • Joshua, Anthony M;
    • Lin, Chia-Chi;
    • Lopez, Juanita;
    • Moreno, Victor;
    • Minchom, Anna;
    • Plummer, Ruth;
    • Postel-Vinay, Sophie;
    • Spreafico, Anna;
    • Shimizu, Toshio
    Publication type:
    Article
    8
    9
    10
    11

    Association of Programmed Death‐Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma Receiving Crizotinib.

    Published in:
    Oncologist, 2020, v. 25, n. 8, p. 702, doi. 10.1634/theoncologist.2020-0088
    By:
    • Yang, Ching‐Yao;
    • Liao, Wei‐Yu;
    • Ho, Chao‐Chi;
    • Chen, Kuan‐Yu;
    • Tsai, Tzu‐Hsiu;
    • Hsu, Chia‐Lin;
    • Liu, Yi‐Nan;
    • Su, Kang‐Yi;
    • Chang, Yih‐Leong;
    • Wu, Chen‐Tu;
    • Liao, Bin‐Chi;
    • Hsu, Chia‐Chi;
    • Hsu, Wei‐Hsun;
    • Lee, Jih‐Hsiang;
    • Lin, Chia‐Chi;
    • Shih, Jin‐Yuan;
    • Yang, James Chih‐Hsin;
    • Yu, Chong‐Jen
    Publication type:
    Article
    12

    An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

    Published in:
    Oncologist, 2019, v. 24, n. 6, p. 747, doi. 10.1634/theoncologist.2018-0838
    By:
    • El Dika, Imane;
    • Lim, Ho Yeong;
    • Yong, Wei Peng;
    • Lin, Chia‐Chi;
    • Yoon, Jung‐Hwan;
    • Modiano, Manuel;
    • Freilich, Bradley;
    • Choi, Hye Jin;
    • Chao, Tsu‐Yi;
    • Kelley, Robin K.;
    • Brown, Joanne;
    • Knox, Jennifer;
    • Ryoo, Baek‐Yeol;
    • Yau, Thomas;
    • Abou‐Alfa, Ghassan K.
    Publication type:
    Article
    13
    14
    15
    16
    17
    18

    Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.

    Published in:
    2020
    By:
    • de Bono, Johann;
    • Lin, Chia-Chi;
    • Chen, Li-Tzong;
    • Corral, Jesus;
    • Michalarea, Vasiliki;
    • Rihawi, Karim;
    • Ong, Michael;
    • Lee, Jih-Hsiang;
    • Hsu, Chih-Hung;
    • Yang, James Chih-Hsin;
    • Shiah, Her-Shyong;
    • Yen, Chia-Jui;
    • Anthoney, Alan;
    • Jove, Maria;
    • Buschke, Susanne;
    • Fuertig, René;
    • Schmid, Ulrike;
    • Goeldner, Rainer-Georg;
    • Strelkowa, Natalja;
    • Huang, Dennis Chin-Lun
    Publication type:
    journal article
    19
    20

    Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

    Published in:
    2018
    By:
    • Mehra, Ranee;
    • Seiwert, Tanguy Y.;
    • Gupta, Shilpa;
    • Weiss, Jared;
    • Gluck, Iris;
    • Eder, Joseph P.;
    • Burtness, Barbara;
    • Tahara, Makoto;
    • Keam, Bhumsuk;
    • Kang, Hyunseok;
    • Muro, Kei;
    • Geva, Ravit;
    • Chung, Hyun Cheol;
    • Lin, Chia-Chi;
    • Aurora-Garg, Deepti;
    • Ray, Archana;
    • Pathiraja, Kumudu;
    • Cheng, Jonathan;
    • Chow, Laura Q. M.;
    • Haddad, Robert
    Publication type:
    journal article
    21
    22

    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

    Published in:
    2017
    By:
    • Reynolds, Kerry Lynn;
    • Bedard, Philippe L.;
    • Se-Hoon Lee;
    • Chia-Chi Lin;
    • Tabernero, Josep;
    • Alsina, Maria;
    • Cohen, Ezra;
    • Baselga, José;
    • Blumenschein Jr., George;
    • Graham, Donna M.;
    • Garrido-Laguna, Ignacio;
    • Juric, Dejan;
    • Sharma, Sunil;
    • Salgia, Ravi;
    • Seroutou, Abdelkader;
    • Xianbin Tian;
    • Fernandez, Rose;
    • Morozov, Alex;
    • Qing Sheng;
    • Ramkumar, Thiruvamoor
    Publication type:
    journal article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y
    By:
    • Chia-Chi Lin;
    • Beeram, Muralidhar;
    • Rowinsky, Eric K.;
    • Takimoto, Chris H.;
    • Ng, Chee M.;
    • Geyer Jr., Charles E.;
    • Denis, Louis J.;
    • De Bono, Johann S.;
    • Hao, Desiree;
    • Tolcher, Anthony W.;
    • Rha, Sun-Young;
    • Jolivet, Jacques;
    • Patnaik, Amita
    Publication type:
    Article
    33

    Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x
    By:
    • Chia-Chi Lin;
    • Calvo, Emiliano;
    • Papadopoulos, Kyriakos P.;
    • Patnaik, Amita;
    • Sarantopoulos, John;
    • Mita, Alain C.;
    • Preston, Glenn G.;
    • Mita, Monica M.;
    • Rodon, Jordi;
    • Mays, Theresa;
    • I.-Tien Yeh;
    • O'Rourke, Pat;
    • Takimoto, Chris H.;
    • Dancey, Janet E.;
    • Chen, Helen;
    • Tolcher, Anthony W.
    Publication type:
    Article
    34
    35

    A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02383-5
    By:
    • Chan, Stephen L.;
    • Schuler, Martin;
    • Kang, Yoon-Koo;
    • Yen, Chia-Jui;
    • Edeline, Julien;
    • Choo, Su Pin;
    • Lin, Chia-Chi;
    • Okusaka, Takuji;
    • Weiss, Karl-Heinz;
    • Macarulla, Teresa;
    • Cattan, Stéphane;
    • Blanc, Jean-Frederic;
    • Lee, Kyung-Hun;
    • Maur, Michela;
    • Pant, Shubham;
    • Kudo, Masatoshi;
    • Assenat, Eric;
    • Zhu, Andrew X.;
    • Yau, Thomas;
    • Lim, Ho Yeong
    Publication type:
    Article
    36
    37
    38
    39
    41

    A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 1, p. 1, doi. 10.1002/cncr.35634
    By:
    • Desai, Jayesh;
    • Wagner, Andrew J.;
    • Carrasco Garcia, Irene;
    • Cesari, Marilena;
    • Gordon, Michael;
    • Lin, Chia‐Chi;
    • Papai, Zsuzsanna;
    • Ryan, Christopher W.;
    • Tap, William D.;
    • Trent, Jonathan C.;
    • Gelderblom, Hans;
    • Grimison, Peter;
    • López Pousa, Antonio;
    • Van Tine, Brian A.;
    • Rubinacci, Maria;
    • Dai, Dong;
    • Rajper, Abdul Waheed;
    • Tecson, Kristen;
    • Wooddell, Margaret;
    • Stacchiotti, Silvia
    Publication type:
    Article
    42

    Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 8, p. 1195, doi. 10.1002/cncr.34657
    By:
    • Oh, Do‐Youn;
    • Algazi, Alain;
    • Capdevila, Jaume;
    • Longo, Federico;
    • Miller, Wilson;
    • Chun Bing, Jerry Tan;
    • Bonilla, Carlos Eduardo;
    • Chung, Hyun Cheol;
    • Guren, Tormod K.;
    • Lin, Chia‐Chi;
    • Motola‐Kuba, Daniel;
    • Shah, Manisha;
    • Hadoux, Julien;
    • Yao, Lili;
    • Jin, Fan;
    • Norwood, Kevin;
    • Lebellec, Loïc
    Publication type:
    Article
    43
    44
    45

    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

    Published in:
    OncoImmunology, 2024, v. 13, n. 1, p. 1, doi. 10.1080/2162402X.2023.2290787
    By:
    • Lin, Chia-Chi;
    • Garralda, Elena;
    • Schöffski, Patrick;
    • Hong, David S.;
    • Siu, Lillian L.;
    • Martin, Miguel;
    • Maur, Michela;
    • Hui, Rina;
    • Soo, Ross A;
    • Chiu, Joanne;
    • Zhang, Tian;
    • Ma, Brigette;
    • Kyi, Chrisann;
    • Tan, Daniel SW;
    • Cassier, Philippe A.;
    • Sarantopoulos, John;
    • Weickhardt, Andrew;
    • Carvajal, Richard D.;
    • Spratlin, Jennifer;
    • Esaki, Taito
    Publication type:
    Article
    46
    47
    48

    Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report.

    Published in:
    Head & Neck, 2025, v. 47, n. 7, p. 1907, doi. 10.1002/hed.28100
    By:
    • Lin, Yen‐Bo;
    • Hu, Hsiang‐Wei;
    • Chung, An‐Ko;
    • Lu, Jin‐Ying;
    • Wu, Wan‐Chen;
    • Chiu, I‐Hsuan;
    • Chu, I;
    • Lin, Chia‐Chi;
    • Lee, Jih‐Hsiang;
    • Nien, Feng‐Jung;
    • Chen, Kuen‐Yuan;
    • Wu, Ming‐Hsun;
    • Chen, Chun‐Nan;
    • Wang, Chun‐Wei;
    • Kuo, Ting‐Chun;
    • Lin, Chia‐Hung;
    • Cheng, Mei‐Fang;
    • Chiu, Wei‐Yih;
    • Kuo, Shuenn‐Wen;
    • Hsih, Wen‐Hui
    Publication type:
    Article
    49
    50